Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea
Main Article Content
Keywords
Rosacea, Minocycline, Topical, Safety, Efficacy
Abstract
References
inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14(2):220-225.
2. Taieb A, Stein Gold L, Feldman SR, et al. Cost-effectiveness of ivermectin 1% cream
in adults with papulopustular rosacea in the United States. J Manag Care Spec Pharm.
2016;22(6):654-665.
3. Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment.
Dermatoendocrinol. 2017;9(1):e131574.
4. Goldgar C, Keahey DJ, Houchins J. Treatment options for acne rosacea. Am Fam
Physician. 2009;80(5):461-468.
5. Oge LK, Munchie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam
Physician. 2015;92(3):187-196.
6. Fiscus V, Hankinson A, Alweis R. Minocycline-induced hyperpigmentation. J Community
Hosp. 2014;4:24063.
7. Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the
treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129-140.
8. Stein Gold L, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate-to-severe papulopustular rosacea: Results
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.